[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489268":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":10,"locations":47,"responsibleParty":71,"collaborators":10,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":10,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":82,"maxAge":10,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",[8,17,21],{"label":9,"type":10,"description":9,"interventionNames":11},"subjects previously infected with COVID-19",null,[12,13,14,15,16],"Device: Dynamic Vessel Analyzer (DVA)","Device: Fourier domain optical coherence tomography (FDOCT)","Device: Optical coherence tomography (OCT)","Device: Laser Speckle Flowgraphy (LSFG)","Diagnostic Test: Proteomics and Metabolites in Plasma, tear fluid and finger sweat",{"label":18,"type":10,"description":19,"interventionNames":20},"subjects with long COVID-19","subjects with long COVID-19 according to the WHO-guideline",[12,13,14,15,16],{"label":22,"type":10,"description":22,"interventionNames":23},"healthy age-and sex- matched control subjects with no history of COVID-19 infection",[12,13,14,15,16],[25,30,34,38,42],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"DEVICE","Dynamic Vessel Analyzer (DVA)","Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA",[22,9,18],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"Fourier domain optical coherence tomography (FDOCT)","Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT",[22,9,18],{"type":26,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"Optical coherence tomography (OCT)","Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT",[22,9,18],{"type":26,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"Laser Speckle Flowgraphy (LSFG)","Normalized blur and Relative flow volume will be assessed using the LSFG",[22,9,18],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":10},"DIAGNOSTIC_TEST","Proteomics and Metabolites in Plasma, tear fluid and finger sweat","Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test",[22,9,18],[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Medical University of Vienna, Department of Clinical Pharmacology","RECRUITING","Vienna","State of Vienna","1090","Austria","AT",{"type":57,"coordinates":58},"Point",[59,60],16.37208,48.20849,{"lat":60,"lon":59},[63,69],{"name":64,"role":65,"phone":66,"phoneExt":67,"email":68},"Doreen Schmidl, MD, PhD","CONTACT","0043140400","29810","klin-pharmakologie@meduniwien.ac.at",{"name":64,"role":70,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":70,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Doreen Schmidl","Associate Professor, MD, PhD","100489268","retinal-neurovascular-coupling-in-patients-previously-infected-with-covid-19-100489268",false,"NCT05650905","Retinal Neurovascular Coupling in Patients Previously Infected With COVID-19","Inclusion Criteria:\n\nInclusion criteria for healthy subjects\n\n* Men and women aged over 18 years\n* Non-smokers\n* Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant\n* No previous history of COVID-19 infection\n* Negative testing for SARS-CoV-2 seroprevalence using nucleocapsid antibody tests\n* Negative PCR test for SARS-CoV-2\n* Normal ophthalmic findings, ametropy \\\u003C 6 Dpt.\n\nInclusion criteria for subjects with history of COVID-19 infection\n\n* Men and women aged over 18 years\n* Non-smokers\n* History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history) within the last 6 months\n* Positive testing for SARS-CoV-2 seroprevalence using spike protein IgG antibody tests\n* Negative PCR test for SARS-CoV-2\n\nInclusion criteria for subjects with long COVID-19\n\n* Men and women aged over 18 years\n* Non-smokers\n* History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history)\n* Positive testing for SARS-CoV-2 seroprevalence\n* Negative PCR test for SARS-CoV-2\n* Long Covid according to the latest WHO-Guidelines\n\nExclusion Criteria:\n\nAny of the following will exclude a healthy control subject from the study:\n\n* Symptoms of a clinically relevant illness in the 3 weeks before the first study day\n* Presence or history of a severe medical condition as judged by the clinical investigator\n* Participation in a clinical trial in the 3 weeks preceding the study\n* Blood donation during the previous three weeks\n* History or family history of epilepsy\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Best corrected visual acuity \\\u003C 0.8 Snellen\n* Pregnancy, planned pregnancy or lactatin\n* History of epilepsia\n\nAny of the following will exclude a subject with history of COVID-19 infection from the study:\n\n* Blood donation during the previous three weeks\n* History or family history of epilepsy\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Best corrected visual acuity \\\u003C 0.8 Snellen\n* Ametropy \\>6 Dpt\n* Pregnancy, planned pregnancy or lactating\n* History of epilepsia\n\nAny of the following will exclude a subject with long COVID-19 from the study:\n\n* Blood donation during the previous three weeks\n* History or family history of epilepsy\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Best corrected visual acuity \\\u003C 0.8 Snellen\n* Ametropy \\>6 Dpt\n* Pregnancy, planned pregnancy or lactating\n* History of epilepsia\n* Diabetes mellitus",true,"ALL","18 Years",{"count":84,"type":85},90,"ESTIMATED","OBSERVATIONAL","The Study objective is to measure retinal neurovascular coupling and blood flow parameters in patients previously infected with COVID-19, long COVID-19 and healthy age- and sex- matched control subjects",[89,90],"COVID-19","Post-COVID-19 Syndrome","2025-05-13",{"date":93,"type":94},"2025-05-16","ACTUAL",{"date":96,"type":94},"2021-07-26",{"date":98,"type":85},"2025-12-31",{"name":5,"class":6},1]